Transaction · 0001231919-26-001152

Ra Capital Management, L.P.

RA CAPITAL MANAGEMENT, L.P., DIR, reported a transaction classified as grant at Artiva Biotherapeutics, Inc. involving 13750.000000 shares for an estimated $0.00. Reported holdings after the transaction were 13750.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ADIR
ARTVArtiva Biotherapeutics, Inc.
Trade date
Sep 08, 2026
Filing date
Sep 08, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded13.7k$0.00 per share
Holdings after13.7kIndirect · See Footnotes
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ARTV price since this filing

Daily closing prices, with the filing date and available return windows
ARTV · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +3.6%1w ago +3.7%1d ago +2.8%
Returns since7d -18.1%30d -37.5%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001231919-26-001152
Director Stock Option (Right to Buy)
Transaction date
Sep 08, 2026
Filed Sep 08, 2026, 10:29 PM · 0d delay
Shares
13,750 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
13,750 sh
Indirect · See Footnotes

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Large Holdings Increase
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% YesOther No
Footnotes & amended
  1. F1

    Represents the grant of a stock option to Laura Stoppel pursuant to the Issuer's non-employee director compensation policy. The shares subject to the option will vest on the earlier of September 8, 20…

  2. F2

    RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P.…

  3. F3

    Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to…

  4. Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting P…

Original filing · 0001231919-26-001152
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ARTV